**Hypertension: Over 1,000 genetic loci influencing blood pressure with multiple systems and tissues implicated**

Claudia P Cabrera1, 2, 3,‡, Fu Liang Ng1, 2,‡, Hannah L Nicholls1, 3, Ajay Gupta1,2, Michael R Barnes1,2,3, Patricia B Munroe1,2, and Mark J Caulfield1, 2, \*

1 Clinical Pharmacology, William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, EC1M 6BQ, UK.

2 NIHR Barts Cardiovascular Biomedical Research Centre, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, EC1M 6BQ, UK.

3 Centre for Translational Bioinformatics, William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, EC1M 6BQ, UK.

‡ The authors wish it to be known that, in their opinion, the first two authors should be regarded as joint First Authors

**Corresponding author:**

Mark J Caulfield

Address: William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London, EC1M 6BQ

Tel: +44 20 7882 3402

Email: m.j.caulfield@qmul.ac.uk

**Abstract**

High blood pressure remains the major heritable and modifiable risk factor for cardiovascular disease (CVD). Persistent high blood pressure, or hypertension, is a complex trait with both genetic and environmental interactions. Despite swift advances in genomics, translating new discoveries to further our understanding of the underlying molecular mechanisms remains a challenge. More than 500 loci implicated in the regulation of blood pressure (BP) have been revealed by genome-wide association studies (GWAS) in 2018 alone, taking the total number of BP genetic loci to over 1,000. Even with the large number of loci now associated to BP, the genetic variance explained by all loci together remains low (~5.7%). These genetic associations have elucidated mechanisms and pathways regulating BP, highlighting potential new therapeutic and drug repurposing targets. A large proportion of the BP loci were discovered and reported simultaneously by multiple research groups, creating a knowledge gap, where the reported loci to date have not been investigated in a harmonious way. Here, we review the BP-associated genetic variants reported across GWAS studies and investigate their potential impact on the biological systems using *in silico* enrichment analyses for pathways, tissues, gene ontology and genetic pleiotropy.

**Introduction**

Cardiovascular diseases, including stroke, renal and heart disease, represent the largest cause of global mortality. The Global Burden of Diseases, Injuries and Risk Factor study calculated ~10.4 million deaths that can be attributed to high systolic blood pressure (SBP) (1) and it is estimated that 25% of the adults have elevated blood pressure (2). To compound this, hypertension is mostly asymptomatic, resulting in the disease being potentially unnoticed until a life-threatening event such as a heart attack or stroke affects the individual.

Individuals with family history of hypertension diagnosed before 55 years of age have been found to have an associated risk to hypertension (odds ratio 2.10 and 1.33 for affected parents and grandparents respectively). These findings reinforce the hypothesis of genetic predisposition to high blood pressure, independent from the environmental factors (3). Blood pressure is a complex polygenic trait, even discussed as a probable omnigenic trait in previous studies (4). The heritability of the common genetic variation in blood pressure has been observed to be ethnicity-dependent. A study in ~8,900 European ancestry individuals estimated the heritability of SBP to be ~20% and approximately 50% for diastolic blood pressure (DBP), whilst heritability in African ancestry individuals (n=2,860) was estimated at ~27% and ~39% respectively (5). While the expected heritability is between 20-50%, the recent analyses indicated that the BP variants identified thus far explains only 27% of the genetic contribution (4), suggesting many loci are yet to be identified.

Here, we review the blood pressure genetic associations unravelled by GWAS, their implications at a pathway and systems level, and investigate the pleiotropy effects of reported blood pressure loci. Collectively these discoveries may bring new mechanistic insights to the treatment of hypertension.

**Blood pressure and genome-wide association studies**

Our understanding of genomic regions linked with BP was rapidly expanded with increasingly large and sophisticated GWAS. Up to 2015, there were 64 validated BP loci reported (6-22). Four years later, the number of known BP loci has increased to 1,477 (4, 23-30), including 1,214 lead signals and 263 secondary signals (Supplementary Table 1; a) Lead BP loci; b) Secondary BP loci). The substantial rise in the reported loci is driven by the collaborative work of international consortia, combined with the availability of public datasets such as UK Biobank (UKB) (31). The UKB data has provided a resource of standardised genotypic and phenotypic data from an unprecedented population size (n=502,620). Other large key resources include the US Million Veteran Program (MVP) (n~318,891) (32), the Genetic Epidemiology Research on Adult Health and Aging cohort (GERA) (n~100,000) (33) and the International Consortium of Blood Pressure (ICBP) (29). To date, the ICBP consortium has accumulated 77 cohorts which include ~299,024 individuals. These studies have paved the way to the biggest analysis reported to date including 1 million people and unravelling 535 novel loci in a single study (4). Figure 1 shows the timeline of some of the key BP GWAS in the last decade and their validated loci.

**BP candidate genes**

The common genetic variants identified as associated with BP continue to improve our understanding of the polygenic nature of blood pressure regulation. Nevertheless, the increased number of loci – and therefore genes – makes the functional investigation of each locus impossible. At the present, there are but a handful of genes followed up by experimental studies (34). While a proportion of the candidate genes at blood pressure loci have been fairly well characterized, many others do not have known links to blood pressure regulation. It is the successes relating to the latter group that highlights the potential to expand our knowledge of the pathophysiology of hypertension. One such example is the transcription factor, Nuclear Receptor 2 Family 2 (*NR2F2*). A murine model with a mutated Nr2f2 protein resulted in lower systolic and diastolic blood pressure, and was more resistant to the hypertensive effects of a high-salt diet. The deletion of a five amino acid hinge region required for the protein-protein interaction with another transcription factor, Fog2 appears to reveal the potential underlying molecular mechanism (35), in particular as the Nr2f2-Fog2 interaction potentially influences expression of the vasorelaxant atrial natriuretic factor (*Anf*) (36).

Another candidate gene of interest is *SH2B3* encoding the lymphocyte adaptor protein LNK. This regulator of cytokine signalling and cell proliferation is predominantly expressed in haematopoietic and endothelial cells. *SH2B3-/-* mice had exaggerated hypertensive responses to angiotensin II, and it is noteworthy that haematopoietic cells were the apparent primary driver of the observed vascular inflammation and predisposition to hypertension (37). However, extensive pleiotropy is observed in the *SH2B3-ATXN2* locus, associations with myocardial infraction, multiple sclerosis, juvenile idiopathic arthritis have been reported (38-40). It should also be recognised that while most of the attention is paid to *SH2B3* as the GWAS signal at rs3184504 results in a coding change within *SH2B3*, this signal falls within a 1-megabase block of linkage disequilibrium on chromosome 12q24 that encompases at least 15 annotated genes (8).

Other examples include genes that are within pathways with known links to BP regulation, such as *ARHGAP42* (Rho GTPase-activating protein 42 gene) in the RhoA pathway. The deletion of *ARHGAP42* in a murine model enhanced the hypertensive effects of both L-NAME and deoxycorticosterone acetate (DOCA)–salt treatments (41). This was later supported by human studies of balanced chromosomal rearrangement carriers resulting in *ARHGAP42* truncation, leading to age-dependent hypertension (42). Finally, *UMOD* (uromodulin), recently reviewed in more detail (34), is another notable candidate gene identified by GWAS. *UMOD* deficient mice have shown to increase sequestration of the target of loop diuretics, the sodium-potassium-chloride co-transporter 2 (KKCC2), resulting in reduced co-transporter activity. This mimics the effect of diuretic drugs, and with the subsequent lower blood pressure and reduced hypertensive response to increased salt intake. The pharmacological inhibition of uromodulin may have a diuretic effect that may perhaps be synergistic with existing pharmacological options (13, 43-45). This has led to a clinical trial on cardiovascular disease (www.clinicaltrials.gov: NCT03354897) (46), making significant progress towards a novel therapeutic target in hypertension.

Altogether, these are examples of translating GWAS discovery to an improved understanding of biological impact, and providing promise of new therapeutic pathways. However, the identification of a true causal variant and the relevant gene product impacted is rarely straightforward. The lead single nucleotide polymorphism (SNP) typically indicates a chromosomal region usually with tens and sometimes thousands of SNPs in linkage disequilibrium (LD) (47), but it may also mark further-away regions with long-range chromatin interactions (48). For example, following the identification of a BP-associated SNP near the *ANTXR2* (anthrax toxin receptor 2) gene, *ANTXR2-/-* knockout rats were generated. The knockout rats exhibited similar BP to wildtype rats, at both basal and stimulated states with either angiotensin II infusion of high-salt diet (49). This can highlight he difficulty in identifying the causal variant or gene within a locus, particularly since this region also encompasses other genes of interest such as *FGF5* (fibroblast growth factor 5). It is often noted that follow-up mechanistic studies are time- and resource-heavy endeavours. With this consideration, we expand on our previous *in silico* analyses, aiming to provide candidate genes for prioritisation in future mechanistic studies.

***In silico* analyses: BP loci pathway and tissue enrichment**

Pathway and tissue enrichment analyses can give us a snapshot on the interactions and downstream consequences of blood pressure loci at a systems level. For the purposes of this review, we investigated all published validated blood pressure signals (lead + secondary) and their SNPs in high LD (r2≥0.8). SNPs were annotated to the nearest gene (within 5kb distance) using bedtools (v2.17) (50), and further characterized using ANNOVAR (51). We performed the following analyses on all the genes annotated to the BP-loci a) tissue enrichment using DEPICT (52); b) gene-set enrichment on pathways using GSEA (53); and c) a permutation based gene-set enrichment analysis on gene ontology (GO) terms using GOfuncR (54, 55).

**Tissue enhancement analyses - DEPICT**

In this tissue enhancement analysis, blood vessels, cardiac and adipose tissues remain in the top most enriched tissues (Table 1), being similar to those presented in Evangelou et al., (2018) (4). The addition of more recently published loci (25) to the analysis, led to an increase of enrichment in mostly all tissues described in previous studies, with the endocrine glands (adrenal cortex, adrenal glands and gonads) and the urogenital system presenting the largest differences between previous studies and the current analysis. The analysis highlighting adrenal tissue is unsurprising with hyperaldosteronism being a well-established secondary cause of hypertension (56), and primary hyperaldosteronism estimated to be responsible for up to 10% of hypertension cases (57, 58). The enrichment in the urogenital system appears driven by genes relating to the myometrium which predominantly consists of uterine smooth muscle cells, which share many similarities with vascular smooth muscle cells. Tissue enrichment analysis also showed for first time enrichment for the exocrine glands and tissues of the digestive system (Table 1). The underlying mechanism of the enrichment observed in the digestive system may reflect the gastro-endocrine pathways which are discussed later on.

**Gene-set enrichment analyses - GSEA**

We revisited the pathway enrichment analysis performed using the Gene-set Enrichment Analysis (GSEA) software we conducted in 2015, where only 81 candidate genes in only eight enriched pathways were described (6). In the updated analysis the latest curated list of 1,630 candidate blood pressure genes annotated to gene-sets highlights more than 200 enriched pathways (Supplementary Table 2 GSEA). Whilst all eight pathways enriched in 2015 remain significant, the calcium signalling pathway and the Reactome gene set of genes involved in haemostasis present the strongest increase in overlapping genes, where both gene-sets are in the top 20 highest-ranked enriched gene-sets (Table 2).

The concept of pathways involving G-protein coupled receptors in blood pressure regulation is unsurprising. Among others, this includes receptors for adrenaline, endothelin, cholinergic transmission, serotonin, and histamine. However, there is also a notable contribution from gastro-endocrine regulation, such as gastric inhibitory polypeptide (*GIP*) and its receptor (*GIPR*), the cholecystokinin B receptor (*CCKBR*) and peptide YY (*PYY*) highlighting the interplay between blood pressure and other metabolic processes. From this selection of potential gastro-endocrine therapeutic targets, perhaps *GIP/GIPR* is the closest to translation to patient care with the recent development of a subcutaneous dual GIP/GLP1 agonist (59), currently intended for use in the management of diabetes. The role of *GIP* in the vasculature has been reviewed in detail by Pujadas and Drucker (60). In summary, various *in vitro* studies have shown GIP as pro-proliferative for endothelial cells (61), with increased endothelin-1 secretion (62). In a study of the development of experimental atherosclerosis, GIP infusion reduced lesion formation. Interestingly, GIP infusion did not affect blood pressure in this murine model (63). This is balanced against limited evidence in healthy volunteer studies of GIP influencing blood flow in some vascular beds during hyperglycaemic phases of a two-step euglycaemic-hyperglycaemic clamp study (64).

There is also a collection of candidate genes involving G-protein coupled receptor pathways that emphasises the key role in neuroregulation of blood pressure, potentially involving gamma-aminobutyric acid (*GABBR1*), opioids (*OPRM1*), neuropeptides (*NPW*) and metabotropic glutamate receptors (*GRM4* and *GRM7*). While there is already some evidence that pharmacological modulation of GABA receptors may influence vascular tone (65), there is no literature thus far on the potential impact of Neuropeptide W and metabotropic glutamate receptors on blood pressure regulation. As G-coupled protein receptors, they represent potentially fruitful avenues for future research.

One other standout result from this pathway analysis is that 48 candidate genes for blood pressure are olfactory receptors. With the caveat that there is hitherto no evidence that genetic variants within olfactory receptors contribute to clinically relevant changes in taste/smell, it has been observed that patients with acquired hyposmia (smell loss) had significant increases in dietary salt intake (66). On a population level, care should be taken when interpreting these results as commonly prescribed antihypertensive and cholesterol-lowering drugs themselves may alter senses of taste and smell (67). Interestingly, there may be a role of olfactory receptors, when ectopically expressed (68), for example in the kidney, where in mouse models *Olfr78* responds to short chain fatty acids with renin secretion, and in turn contributes to blood pressure regulation (69). The human ortholog of *Olfr78* (*OR51E2*) is notably situated near its family member *OR51E1*, which is also blood pressure candidate gene (4).

Another grouping of would-be therapeutic targets may be from the extracellular matrix pathway. This includes gene products within the extracellular matrix itself (e.g. fibronectin, collagen, fibrillin, and thrombospondin), hormones (e.g. transforming growth factor, vascular endothelial growth factor, fibroblast growth factor and platelet-derived growth factor) and enzymes that regulate the extracellular matrix (e.g. matrix metallopeptidases and ADAM metallopeptidase with thrombospondin enzymes). The potential for many of these candidate genes as therapeutic targets may stem from also being overlapping GWAS candidate genes for ischaemic heart disease (70, 71), allowing for therapeutic agents with the possibility of pleotropic effects.

**Gene ontology analyses – GofuncR and REVIGO**

Gene ontology enrichment analyses were visualized using REVIGO. This tool calculates the semantic similarity between GO terms and aids their visualization (72). There are two main clusters observed in the GO plot for biological processes (Figure 2). While one cluster (A) is unsurprising, including broad intracellular functions such as regulation of intracellular signal transduction, cell cycle, organelle organization, cellular localization, cellular process and transcription, the second cluster (B) may be more revealing in terms of potential new understanding of the biology underlying blood pressure regulation. Within this cluster, the five major gene ontology terms refer to biosynthesis of nucleobase-containing compounds, organic cyclic compounds, aromatic compounds, cellular nitrogen compounds and heterocyclic compounds. While there are commonly recognised enzymes within these groups contributing to the regulation of blood pressure (e.g. adenylate and guanylate cyclases, and adenosine kinases), there are three other enzymes here which we felt were worth highlighting.

Carbamoyl-phosphate synthase 1 (*CPS1*) is the enzyme that catalyses the rate-limiting step in the urea cycle and L-citrulline production. This reaction allows vascular endothelial cells to recycle the by-product of nitric oxide synthesis, L-citrulline, by using components of the urea cycle. The naturally occurring T1405N variation within *CPS1* is already known to vascular dynamics in an experimental setting (73). *MTAP* (encoding S-methyl-5'-thioadenosine phosphorylase) is also an interesting potential target as an important in the salvage of adenine and methionine. It also resides in the 9p21 region, with the strongest GWAS signal for coronary artery disease and myocardial (74, 75). Mice heterozygous for *MTAP* shows increased predisposition to atherosclerotic lesions (76), which may allow for the development of therapeutic options that has pleotropic effects. It should however be recognised that there are also multiple other genes of interest in the 9p21 region, including the tumour suppressor genes *CDKN2A* and *CDKN2*, and the long non-coding RNA *ANRIL*. *DBH* encodes dopamine β-hydroxylase which catalyses the conversion of dopamine to norepinephrine. It is predominantly expressed in neural and adrenal tissues, and is involved in noradrenergic transmission of central and peripheral nervous systems. More recently, its expression has been detected in endothelial cells, where dopamine β-hydroxylase inhibition reduces *in vitro* angiogenesis (77). This enzyme also potentially plays a role in vascular wall remodelling, where *DBH-/-* mice has attenuated vessel injury-induced medial hypertrophy compared to wildtype littermates (78).

**Multi-trait BP associations**

BP-variants have been reported to have many other genetic associations (4, 6, 79). Here, we interrogated the GWAS Catalog for all traits associated with the BP-variants (n=45.9k) (80). After applying a stricter p-value association threshold (–log10 p-value < 10.5), these results were manually curated and summarized on the mapped genes. After excluding blood pressure traits (e.g. SBP, DBP, and PP), cardiovascular disease, red blood cell counts, body mass index and type 2 diabetes were the traits with increased numbers of BP-variant associations. The co-occurrence observed between BP variants and other traits could be highlighting pleiotropy effects, where the associated variant impacts overlapping causal pathways for each phenotype. However, this co-occurrence could also possibly be due to BP being affected by other traits. Figure 3 shows all BP loci with more than five associations with at least four traits. Two clusters of interest can be observed, with several genes demonstrating potential such as cholesterol levels, diabetes, obesity, and cardiovascular disease itself. These genes include *APOE, LDLR, FGF5, SLC39A8*, *FUT2, FTO and SH2B3-ATXN2*. Our group has previously demonstrated the role of the blood-pressure associated non-synonymous polymorphism at *SLC39A8* influencing *in vitro* intracellular cadmium accumulation and subsequent toxicity (81).

**The landscape and future of BP genetics**

The genetic research community realised at early stages of GWAS that the sample sizes needed to be very large and also dependent on the number of SNPs been tested (82). As the sample sizes increased, substantial number of loci associated to traits and disease started to be uncovered. The ~1,477 validated blood pressure associations reported to date have been achieved by analysing over 1 million individuals (4, 7-29). Yet, approximately 73% of the genetic variance remains unaccounted for (4).

The genetics of hypertension and blood pressure prove to be highly complex. The associated BP loci are localized across the whole genome, and their annotations revealed enrichment in some obvious blood pressure pathways, but they also revealed hundreds of other pathways and tissues with no direct known connections to BP. Here, we only observed two pathways previously enriched (the calcium signalling pathway and genes involved in haemostasis) maintaining their status as “top” enriched pathways. These discoveries are contrary to the initial idea that the unravelling of new loci would first fill in the gaps of the already known pathways, and instead we observe the enrichment of systems and tissues with no prior knowledge on BP regulation. However, BP loci have been found to have multiple associations across traits (e.g. Type II diabetes, obesity, and cholesterol among others) showing strong evidence of pleiotropy (83) and this is challenging for the characterization of loci specific to BP.

The number of genes and variants uncovered by GWAS means there is a great challenge for traditional functional studies. There seems to be only a few successful follow up studies on candidate genes identified through GWAS relative to the numerous loci reported. However, this should be viewed in context of the lag-time between GWAS and publication of mechanistic studies that is often in the range of 3-5 years. With that, it may be reasonable to suggest more mechanistic studies are to follow with the massively expanded candidate gene list. *In silico* follow-up, the utilization of resources such as ENCODE (84) and GTEx (85), are becoming increasingly more important, where the next task is to prioritise the genes that may be most likely to bear fruitful clinical translation. For example, the application of deep neural networks to prioritise blood pressure genes, converging data from a range of genomic annotation resources on the blood pressure associated genes identified by GWAS; providing model training and testing datasets. Exploring the systems biology of these prioritised genes may offer new mechanistic insights and therapeutic targets.

BP genetic associations have shed light into mechanisms and the architecture of blood pressure. However, there are two main drawbacks on most of these GWAS studies, 1) they are largely based on individuals with European descent and 2) due to most GWAS based on imputed SNP arrays, where imputation performs poorly in regions with low LD (86), they are generally restricted to the analysis of common variants (minor allele frequency > 1%). Expanding research into rare variants proved to be extraordinarily fruitful for Wainshctein and colleagues, who succeeded to recover all the heritability from height using whole-genome sequencing, but there has been limited research to date on the impact of rare variants on blood pressure regulation (27, 28). The missing heritability in height was unearthed from rare variants in regions of low LD (87). The availability of whole genomes and initiatives such as Genomics England could pave the way to investigate all variants, including structural and non-coding variants, allowing us to expand our knowledge and discover the hidden genetic variance in blood pressure.

**Acknowledgements**

This works forms part of the research areas contributing to the Cardiovascular Biomedical Research Centre at Barts Health NHS Trust which is supported and funded by the National Institute for Health Research.

**Conflict of Interest Statement**

No conflicts of interest to disclose

**References**

1 (2018) Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet*, **392**, 1923-1994.

2 Forouzanfar, M.H., Liu, P., Roth, G.A., Ng, M., Biryukov, S., Marczak, L., Alexander, L., Estep, K., Hassen Abate, K., Akinyemiju, T.F. *et al.* (2017) Global Burden of Hypertension and Systolic Blood Pressure of at Least 110 to 115 mm Hg, 1990-2015. *Jama*, **317**, 165-182.

3 Niiranen, T.J., McCabe, E.L., Larson, M.G., Henglin, M., Lakdawala, N.K., Vasan, R.S. and Cheng, S. (2017) Risk for hypertension crosses generations in the community: a multi-generational cohort study. *Eur. Heart. J.*, **38**, 2300-2308.

4 Evangelou, E., Warren, H.R., Mosen-Ansorena, D., Mifsud, B., Pazoki, R., Gao, H., Ntritsos, G., Dimou, N., Cabrera, C.P., Karaman, I. *et al.* (2018) Genetic analysis of over 1 million people identifies 535 new loci associated with blood pressure traits. *Nat. Genet.*, **50**, 1412-1425.

5 Salfati, E., Morrison, A.C., Boerwinkle, E. and Chakravarti, A. (2015) Direct Estimates of the Genomic Contributions to Blood Pressure Heritability within a Population-Based Cohort (ARIC). *PLOS ONE*, **10**, e0133031.

6 Cabrera, C.P., Ng, F.L., Warren, H.R., Barnes, M.R., Munroe, P.B. and Caulfield, M.J. (2015) Exploring hypertension genome-wide association studies findings and impact on pathophysiology, pathways, and pharmacogenetics. *Wiley. Interdiscip. Rev. Syst. Biol. Med.*, **7**, 73-90.

7 Newton-Cheh, C., Johnson, T., Gateva, V., Tobin, M.D., Bochud, M., Coin, L., Najjar, S.S., Zhao, J.H., Heath, S.C., Eyheramendy, S. *et al.* (2009) Genome-wide association study identifies eight loci associated with blood pressure. *Nat. Genet.*, **41**, 666-676.

8 Levy, D., Ehret, G.B., Rice, K., Verwoert, G.C., Launer, L.J., Dehghan, A., Glazer, N.L., Morrison, A.C., Johnson, A.D., Aspelund, T. *et al.* (2009) Genome-wide association study of blood pressure and hypertension. *Nat. Genet.*, **41**, 677-687.

9 Ehret, G.B., Munroe, P.B., Rice, K.M., Bochud, M., Johnson, A.D., Chasman, D.I., Smith, A.V., Tobin, M.D., Verwoert, G.C., Hwang, S.J. *et al.* (2011) Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. *Nature*, **478**, 103-109.

10 Cho, Y.S., Go, M.J., Kim, Y.J., Heo, J.Y., Oh, J.H., Ban, H.J., Yoon, D., Lee, M.H., Kim, D.J., Park, M. *et al.* (2009) A large-scale genome-wide association study of Asian populations uncovers genetic factors influencing eight quantitative traits. *Nat. Genet.*, **41**, 527-534.

11 Franceschini, N., Fox, E., Zhang, Z., Edwards, T.L., Nalls, M.A., Sung, Y.J., Tayo, B.O., Sun, Y.V., Gottesman, O., Adeyemo, A. *et al.* (2013) Genome-wide association analysis of blood-pressure traits in African-ancestry individuals reveals common associated genes in African and non-African populations. *Am. J. Hum. Genet.*, **93**, 545-554.

12 Ganesh, S.K., Tragante, V., Guo, W., Guo, Y., Lanktree, M.B., Smith, E.N., Johnson, T., Castillo, B.A., Barnard, J., Baumert, J. *et al.* (2013) Loci influencing blood pressure identified using a cardiovascular gene-centric array. *Hum. Mol. Genet.*, **22**, 1663-1678.

13 Padmanabhan, S., Melander, O., Johnson, T., Di Blasio, A.M., Lee, W.K., Gentilini, D., Hastie, C.E., Menni, C., Monti, M.C., Delles, C. *et al.* (2010) Genome-wide association study of blood pressure extremes identifies variant near UMOD associated with hypertension. *PLoS Genet.*, **6**, e1001177.

14 Kato, N., Takeuchi, F., Tabara, Y., Kelly, T.N., Go, M.J., Sim, X., Tay, W.T., Chen, C.H., Zhang, Y., Yamamoto, K. *et al.* (2011) Meta-analysis of genome-wide association studies identifies common variants associated with blood pressure variation in east Asians. *Nat. Genet.*, **43**, 531-538.

15 Takeuchi, F., Isono, M., Katsuya, T., Yamamoto, K., Yokota, M., Sugiyama, T., Nabika, T., Fujioka, A., Ohnaka, K., Asano, H. *et al.* (2010) Blood pressure and hypertension are associated with 7 loci in the Japanese population. *Circulation*, **121**, 2302-2309.

16 Tragante, V., Barnes, M.R., Ganesh, S.K., Lanktree, M.B., Guo, W., Franceschini, N., Smith, E.N., Johnson, T., Holmes, M.V., Padmanabhan, S. *et al.* (2014) Gene-centric meta-analysis in 87,736 individuals of European ancestry identifies multiple blood-pressure-related loci. *Am. J. Hum. Genet.*, **94**, 349-360.

17 Wain, L.V., Verwoert, G.C., O'Reilly, P.F., Shi, G., Johnson, T., Johnson, A.D., Bochud, M., Rice, K.M., Henneman, P., Smith, A.V. *et al.* (2011) Genome-wide association study identifies six new loci influencing pulse pressure and mean arterial pressure. *Nat. Genet.*, **43**, 1005-1011.

18 Simino, J., Shi, G., Bis, J.C., Chasman, D.I., Ehret, G.B., Gu, X., Guo, X., Hwang, S.J., Sijbrands, E., Smith, A.V. *et al.* (2014) Gene-age interactions in blood pressure regulation: a large-scale investigation with the CHARGE, Global BPgen, and ICBP Consortia. *Am. J. Hum. Genet.*, **95**, 24-38.

19 Johnson, T., Gaunt, T.R., Newhouse, S.J., Padmanabhan, S., Tomaszewski, M., Kumari, M., Morris, R.W., Tzoulaki, I., O'Brien, E.T., Poulter, N.R. *et al.* (2011) Blood pressure loci identified with a gene-centric array. *Am. J. Hum. Genet.*, **89**, 688-700.

20 Johnson, A.D., Newton-Cheh, C., Chasman, D.I., Ehret, G.B., Johnson, T., Rose, L., Rice, K., Verwoert, G.C., Launer, L.J., Gudnason, V. *et al.* (2011) Association of hypertension drug target genes with blood pressure and hypertension in 86,588 individuals. *Hypertension*, **57**, 903-910.

21 Ho, J.E., Levy, D., Rose, L., Johnson, A.D., Ridker, P.M. and Chasman, D.I. (2011) Discovery and replication of novel blood pressure genetic loci in the Women's Genome Health Study. *J. Hypertens.*, **29**, 62-69.

22 Ganesh, S.K., Chasman, D.I., Larson, M.G., Guo, X., Verwoert, G., Bis, J.C., Gu, X., Smith, A.V., Yang, M.L., Zhang, Y. *et al.* (2014) Effects of long-term averaging of quantitative blood pressure traits on the detection of genetic associations. *Am. J. Hum. Genet.*, **95**, 49-65.

23 Warren, H.R., Evangelou, E., Cabrera, C.P., Gao, H., Ren, M., Mifsud, B., Ntalla, I., Surendran, P., Liu, C., Cook, J.P. *et al.* (2017) Genome-wide association analysis identifies novel blood pressure loci and offers biological insights into cardiovascular risk. *Nat. Genet.*, **49**, 403-415.

24 Hoffmann, T.J., Ehret, G.B., Nandakumar, P., Ranatunga, D., Schaefer, C., Kwok, P.Y., Iribarren, C., Chakravarti, A. and Risch, N. (2017) Genome-wide association analyses using electronic health records identify new loci influencing blood pressure variation. *Nat. Genet.*, **49**, 54-64.

25 Giri, A., Hellwege, J.N., Keaton, J.M., Park, J., Qiu, C., Warren, H.R., Torstenson, E.S., Kovesdy, C.P., Sun, Y.V., Wilson, O.D. *et al.* (2019) Trans-ethnic association study of blood pressure determinants in over 750,000 individuals. *Nat. Genet.*, **51**, 51-62.

26 Ehret, G.B., Ferreira, T., Chasman, D.I., Jackson, A.U., Schmidt, E.M., Johnson, T., Thorleifsson, G., Luan, J., Donnelly, L.A., Kanoni, S. *et al.* (2016) The genetics of blood pressure regulation and its target organs from association studies in 342,415 individuals. *Nat. Genet.*, **48**, 1171-1184.

27 Liu, C., Kraja, A.T., Smith, J.A., Brody, J.A., Franceschini, N., Bis, J.C., Rice, K., Morrison, A.C., Lu, Y., Weiss, S. *et al.* (2016) Meta-analysis identifies common and rare variants influencing blood pressure and overlapping with metabolic trait loci. *Nat. Genet.*, **48**, 1162-1170.

28 Surendran, P., Drenos, F., Young, R., Warren, H., Cook, J.P., Manning, A.K., Grarup, N., Sim, X., Barnes, D.R., Witkowska, K. *et al.* (2016) Trans-ancestry meta-analyses identify rare and common variants associated with blood pressure and hypertension. *Nat. Genet.*, **48**, 1151-1161.

29 Wain, L.V., Vaez, A., Jansen, R., Joehanes, R., van der Most, P.J., Erzurumluoglu, A.M., O'Reilly, P.F., Cabrera, C.P., Warren, H.R., Rose, L.M. *et al.* (2017) Novel Blood Pressure Locus and Gene Discovery Using Genome-Wide Association Study and Expression Data Sets From Blood and the Kidney. *Hypertension*, in press.

30 Kraja, A.T., Cook, J.P., Warren, H.R., Surendran, P., Liu, C., Evangelou, E., Manning, A.K., Grarup, N., Drenos, F., Sim, X. *et al.* (2017) New Blood Pressure-Associated Loci Identified in Meta-Analyses of 475 000 Individuals. *Circ. Cardiovasc. Genet.*, **10**.

31 Sudlow, C., Gallacher, J., Allen, N., Beral, V., Burton, P., Danesh, J., Downey, P., Elliott, P., Green, J., Landray, M. *et al.* (2015) UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. *PLoS Med*, **12**, e1001779.

32 Gaziano, J.M., Concato, J., Brophy, M., Fiore, L., Pyarajan, S., Breeling, J., Whitbourne, S., Deen, J., Shannon, C., Humphries, D. *et al.* (2016) Million Veteran Program: A mega-biobank to study genetic influences on health and disease. *J. Clin. Epidemiol.*, **70**, 214-223.

33 Kvale, M.N., Hesselson, S., Hoffmann, T.J., Cao, Y., Chan, D., Connell, S., Croen, L.A., Dispensa, B.P., Eshragh, J., Finn, A. *et al.* (2015) Genotyping Informatics and Quality Control for 100,000 Subjects in the Genetic Epidemiology Research on Adult Health and Aging (GERA) Cohort. *Genetics*, **200**, 1051-1060.

34 Ng, F.L., Warren, H.R. and Caulfield, M.J. (2018) Hypertension genomics and cardiovascular prevention. *Ann. Transl. Med.*, **6**, 291.

35 Kumarasamy, S., Waghulde, H., Gopalakrishnan, K., Mell, B., Morgan, E. and Joe, B. (2015) Mutation within the hinge region of the transcription factor Nr2f2 attenuates salt-sensitive hypertension. *Nat. Commun.*, **6**, 6252.

36 Huggins, G.S., Bacani, C.J., Boltax, J., Aikawa, R. and Leiden, J.M. (2001) Friend of GATA 2 physically interacts with chicken ovalbumin upstream promoter-TF2 (COUP-TF2) and COUP-TF3 and represses COUP-TF2-dependent activation of the atrial natriuretic factor promoter. *J. Biol. Chem.*, **276**, 28029-28036.

37 Saleh, M.A., McMaster, W.G., Wu, J., Norlander, A.E., Funt, S.A., Thabet, S.R., Kirabo, A., Xiao, L., Chen, W., Itani, H.A. *et al.* (2015) Lymphocyte adaptor protein LNK deficiency exacerbates hypertension and end-organ inflammation. *J. Clin. Invest.*, **125**, 1189-1202.

38 Hunt, K.A., Zhernakova, A., Turner, G., Heap, G.A., Franke, L., Bruinenberg, M., Romanos, J., Dinesen, L.C., Ryan, A.W., Panesar, D. *et al.* (2008) Newly identified genetic risk variants for celiac disease related to the immune response. *Nat. Genet.*, **40**, 395-402.

39 Gudbjartsson, D.F., Bjornsdottir, U.S., Halapi, E., Helgadottir, A., Sulem, P., Jonsdottir, G.M., Thorleifsson, G., Helgadottir, H., Steinthorsdottir, V., Stefansson, H. *et al.* (2009) Sequence variants affecting eosinophil numbers associate with asthma and myocardial infarction. *Nat. Genet.*, **41**, 342-347.

40 Alcina, A., Vandenbroeck, K., Otaegui, D., Saiz, A., Gonzalez, J.R., Fernandez, O., Cavanillas, M.L., Cenit, M.C., Arroyo, R., Alloza, I. *et al.* (2010) The autoimmune disease-associated KIF5A, CD226 and SH2B3 gene variants confer susceptibility for multiple sclerosis. *Genes. Immun.*, **11**, 439-445.

41 Bai, X., Mangum, K.D., Dee, R.A., Stouffer, G.A., Lee, C.R., Oni-Orisan, A., Patterson, C., Schisler, J.C., Viera, A.J., Taylor, J.M. *et al.* (2017) Blood pressure-associated polymorphism controls ARHGAP42 expression via serum response factor DNA binding. *J. Clin. Invest.*, **127**, 670-680.

42 Fjorder, A.S., Rasmussen, M.B., Mehrjouy, M.M., Nazaryan-Petersen, L., Hansen, C., Bak, M., Grarup, N., Norremolle, A., Larsen, L.A., Vestergaard, H. *et al.* (2019) Haploinsufficiency of ARHGAP42 is associated with hypertension. *Eur. J. Hum. Genet.*, in press.

43 Mutig, K., Kahl, T., Saritas, T., Godes, M., Persson, P., Bates, J., Raffi, H., Rampoldi, L., Uchida, S., Hille, C. *et al.* (2011) Activation of the bumetanide-sensitive Na+,K+,2Cl- cotransporter (NKCC2) is facilitated by Tamm-Horsfall protein in a chloride-sensitive manner. *J. Biol. Chem.*, **286**, 30200-30210.

44 Graham, L.A., Padmanabhan, S., Fraser, N.J., Kumar, S., Bates, J.M., Raffi, H.S., Welsh, P., Beattie, W., Hao, S., Leh, S. *et al.* (2014) Validation of uromodulin as a candidate gene for human essential hypertension. *Hypertension*, **63**, 551-558.

45 Trudu, M., Janas, S., Lanzani, C., Debaix, H., Schaeffer, C., Ikehata, M., Citterio, L., Demaretz, S., Trevisani, F., Ristagno, G. *et al.* (2013) Common noncoding UMOD gene variants induce salt-sensitive hypertension and kidney damage by increasing uromodulin expression. *Nat. Med.*, **19**, 1655-1660.

46 Padmanabhan, S., Aman, A. and Dominiczak, A.F. (2018) Recent Findings in the Genetics of Blood Pressure: How to Apply in Practice or Is a Moonshot Required? *Curr. Hypertens. Rep.*, **20**, 54.

47 Munroe, P.B., Barnes, M.R. and Caulfield, M.J. (2013) Advances in blood pressure genomics. *Circ. Res.*, **112**, 1365-1379.

48 Schmitt, A.D., Hu, M., Jung, I., Xu, Z., Qiu, Y., Tan, C.L., Li, Y., Lin, S., Lin, Y., Barr, C.L. *et al.* (2016) A Compendium of Chromatin Contact Maps Reveals Spatially Active Regions in the Human Genome. *Cell. Rep.*, **17**, 2042-2059.

49 Liu, X., Yuan, W., Li, J., Yang, L. and Cai, J. (2017) ANTXR2 Knock-Out Does Not Result in the Development of Hypertension in Rats. *Am. J. Hypertens.*, **30**, 182-187.

50 Quinlan, A.R. and Hall, I.M. (2010) BEDTools: a flexible suite of utilities for comparing genomic features. *Bioinformatics*, **26**, 841-842.

51 Wang, K., Li, M. and Hakonarson, H. (2010) ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. *Nucleic Acids Res.*, **38**, e164.

52 Pers, T.H., Karjalainen, J.M., Chan, Y., Westra, H.J., Wood, A.R., Yang, J., Lui, J.C., Vedantam, S., Gustafsson, S., Esko, T. *et al.* (2015) Biological interpretation of genome-wide association studies using predicted gene functions. *Nat. Commun.*, **6**, 5890.

53 Subramanian, A., Tamayo, P., Mootha, V.K., Mukherjee, S., Ebert, B.L., Gillette, M.A., Paulovich, A., Pomeroy, S.L., Golub, T.R., Lander, E.S. *et al.* (2005) Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. *Proc. Natl. Acad. Sci. U. S. A.*, **102**, 15545-15550.

54 Grote, S. (2018) GOfuncR: Gene ontology enrichment using FUNC. in press.

55 Prüfer, K., Muetzel, B., Do, H.-H., Weiss, G., Khaitovich, P., Rahm, E., Pääbo, S., Lachmann, M. and Enard, W. (2007) FUNC: a package for detecting significant associations between gene sets and ontological annotations. *BMC bioinformatics*, **8**, 41-41.

56 Carretero, O.A., Enzmann, G., Polomski, C., Piwonska, A., Oza, N.B. and Schork, A. (1973) Role of the adrenal glands in the development of severe hypertension. *Circ. Res.*, **33**, 516-520.

57 Rossi, G., Bernini, G., Caliumi, C., Desideri, G., Fabris, B., Ferri, C., Ganzaroli, C., Giacchetti, G., Letizia, C. and Maccario, M. (2006) A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. *Journal of the American College of Cardiology*, **48**, 2293-2300.

58 Douma, S., Petidis, K., Doumas, M., Papaefthimiou, P., Triantafyllou, A., Kartali, N., Papadopoulos, N., Vogiatzis, K. and Zamboulis, C. (2008) Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study. *Lancet*, **371**, 1921-1926.

59 Portron, A., Jadidi, S., Sarkar, N., DiMarchi, R. and Schmitt, C. (2017) Pharmacodynamics, pharmacokinetics, safety and tolerability of the novel dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 agonist RG7697 after single subcutaneous administration in healthy subjects. *Diabetes Obes. Metab.*, **19**, 1446-1453.

60 Pujadas, G. and Drucker, D.J. (2016) Vascular Biology of Glucagon Receptor Superfamily Peptides: Mechanistic and Clinical Relevance. *Endocr. Rev.*, **37**, 554-583.

61 Ding, K.H., Zhong, Q. and Isales, C.M. (2003) Glucose-dependent insulinotropic peptide stimulates thymidine incorporation in endothelial cells: role of endothelin-1. *Am. J. Physiol. Endocrinol. Metab.*, **285**, E390-396.

62 Ding, K.H., Zhong, Q., Xu, J. and Isales, C.M. (2004) Glucose-dependent insulinotropic peptide: differential effects on hepatic artery vs. portal vein endothelial cells. *Am. J. Physiol. Endocrinol. Metab.*, **286**, E773-779.

63 Nogi, Y., Nagashima, M., Terasaki, M., Nohtomi, K., Watanabe, T. and Hirano, T. (2012) Glucose-dependent insulinotropic polypeptide prevents the progression of macrophage-driven atherosclerosis in diabetic apolipoprotein E-null mice. *PLoS One*, **7**, e35683.

64 Karstoft, K., Mortensen, S.P., Knudsen, S.H. and Solomon, T.P. (2015) Direct effect of incretin hormones on glucose and glycerol metabolism and hemodynamics. *Am. J. Physiol. Endocrinol. Metab.*, **308**, E426-433.

65 Kamran, M., Bahrami, A., Soltani, N., Keshavarz, M. and Farsi, L. (2013) GABA-induced vasorelaxation mediated by nitric oxide and GABAA receptor in non diabetic and streptozotocin-induced diabetic rat vessels. *Gen. Physiol. Biophys.*, **32**, 101-106.

66 Henkin, R.I. (2014) Effects of smell loss (hyposmia) on salt usage. *Nutrition*, **30**, 690-695.

67 Doty, R.L., Philip, S., Reddy, K. and Kerr, K.L. (2003) Influences of antihypertensive and antihyperlipidemic drugs on the senses of taste and smell: a review. *J. Hypertens.*, **21**, 1805-1813.

68 Lee, S.J., Depoortere, I. and Hatt, H. (2019) Therapeutic potential of ectopic olfactory and taste receptors. *Nat. Rev. Drug. Discov.*, **18**, 116-138.

69 Pluznick, J.L., Protzko, R.J., Gevorgyan, H., Peterlin, Z., Sipos, A., Han, J., Brunet, I., Wan, L.X., Rey, F., Wang, T. *et al.* (2013) Olfactory receptor responding to gut microbiota-derived signals plays a role in renin secretion and blood pressure regulation. *Proc. Natl. Acad. Sci. U. S. A.*, **110**, 4410-4415.

70 Nikpay, M., Goel, A., Won, H.H., Hall, L.M., Willenborg, C., Kanoni, S., Saleheen, D., Kyriakou, T., Nelson, C.P., Hopewell, J.C. *et al.* (2015) A comprehensive 1,000 Genomes-based genome-wide association meta-analysis of coronary artery disease. *Nat. Genet.*, **47**, 1121-1130.

71 Nelson, C.P., Goel, A., Butterworth, A.S., Kanoni, S., Webb, T.R., Marouli, E., Zeng, L., Ntalla, I., Lai, F.Y., Hopewell, J.C. *et al.* (2017) Association analyses based on false discovery rate implicate new loci for coronary artery disease. *Nat. Genet.*, **49**, 1385-1391.

72 Supek, F., Bošnjak, M., Škunca, N. and Šmuc, T. (2011) REVIGO Summarizes and Visualizes Long Lists of Gene Ontology Terms. *PLOS ONE*, **6**, e21800.

73 Summar, M.L., Gainer, J.V., Pretorius, M., Malave, H., Harris, S., Hall, L.D., Weisberg, A., Vaughan, D.E., Christman, B.W. and Brown, N.J. (2004) Relationship between carbamoyl-phosphate synthetase genotype and systemic vascular function. *Hypertension*, **43**, 186-191.

74 Samani, N.J., Erdmann, J., Hall, A.S., Hengstenberg, C., Mangino, M., Mayer, B., Dixon, R.J., Meitinger, T., Braund, P., Wichmann, H.E. *et al.* (2007) Genomewide association analysis of coronary artery disease. *N. Engl. J. Med.*, **357**, 443-453.

75 Helgadottir, A., Thorleifsson, G., Manolescu, A., Gretarsdottir, S., Blondal, T., Jonasdottir, A., Jonasdottir, A., Sigurdsson, A., Baker, A., Palsson, A. *et al.* (2007) A common variant on chromosome 9p21 affects the risk of myocardial infarction. *Science*, **316**, 1491-1493.

76 Kim, J.B., Deluna, A., Mungrue, I.N., Vu, C., Pouldar, D., Civelek, M., Orozco, L., Wu, J., Wang, X., Charugundla, S. *et al.* (2012) Effect of 9p21.3 coronary artery disease locus neighboring genes on atherosclerosis in mice. *Circulation*, **126**, 1896-1906.

77 Sorriento, D., Santulli, G., Del Giudice, C., Anastasio, A., Trimarco, B. and Iaccarino, G. (2012) Endothelial cells are able to synthesize and release catecholamines both in vitro and in vivo. *Hypertension*, **60**, 129-136.

78 Zhang, H., Cotecchia, S., Thomas, S.A., Tanoue, A., Tsujimoto, G. and Faber, J.E. (2004) Gene deletion of dopamine beta-hydroxylase and alpha1-adrenoceptors demonstrates involvement of catecholamines in vascular remodeling. *Am. J. Physiol. Heart. Circ. Physiol.*, **287**, H2106-2114.

79 Ma, M.C.J., Pettus, J.M., Jakoubek, J.A., Traxler, M.G., Clark, K.C., Mennie, A.K. and Kwitek, A.E. (2017) Contribution of independent and pleiotropic genetic effects in the metabolic syndrome in a hypertensive rat. *PLoS One*, **12**, e0182650.

80 MacArthur, J., Bowler, E., Cerezo, M., Gil, L., Hall, P., Hastings, E., Junkins, H., McMahon, A., Milano, A., Morales, J. *et al.* (2017) The new NHGRI-EBI Catalog of published genome-wide association studies (GWAS Catalog). *Nucleic. Acids. Res.*, **45**, D896-d901.

81 Zhang, R., Witkowska, K., Afonso Guerra-Assuncao, J., Ren, M., Ng, F.L., Mauro, C., Tucker, A.T., Caulfield, M.J. and Ye, S. (2016) A blood pressure-associated variant of the SLC39A8 gene influences cellular cadmium accumulation and toxicity. *Hum. Mol. Genet.*, **25**, 4117-4126.

82 Hong, E.P. and Park, J.W. (2012) Sample size and statistical power calculation in genetic association studies. *Genomics & informatics*, **10**, 117-122.

83 Denny, J.C., Bastarache, L., Ritchie, M.D., Carroll, R.J., Zink, R., Mosley, J.D., Field, J.R., Pulley, J.M., Ramirez, A.H., Bowton, E. *et al.* (2013) Systematic comparison of phenome-wide association study of electronic medical record data and genome-wide association study data. *Nature biotechnology*, **31**, 1102-1110.

84 Davis, C.A., Hitz, B.C., Sloan, C.A., Chan, E.T., Davidson, J.M., Gabdank, I., Hilton, J.A., Jain, K., Baymuradov, U.K., Narayanan, A.K. *et al.* (2018) The Encyclopedia of DNA elements (ENCODE): data portal update. *Nucleic. Acids. Res.*, **46**, D794-d801.

85 (2015) Human genomics. The Genotype-Tissue Expression (GTEx) pilot analysis: multitissue gene regulation in humans. *Science*, **348**, 648-660.

86 Van Hout, C.V., Tachmazidou, I., Backman, J.D., Hoffman, J.X., Ye, B., Pandey, A.K., Gonzaga-Jauregui, C., Khalid, S., Liu, D., Banerjee, N. *et al.* (2019) Whole exome sequencing and characterization of coding variation in 49,960 individuals in the UK Biobank. *bioRxiv*, in press., 572347.

87 Wainschtein, P., Jain, D.P., Yengo, L., Zheng, Z., Cupples, L.A., Shadyab, A.H., McKnight, B., Shoemaker, B.M., Mitchell, B.D., Psaty, B.M. *et al.* (2019) Recovery of trait heritability from whole genome sequence data. *bioRxiv*, in press., 588020.

**Figure Legends**

**Figure 1. Timeline of validated blood pressure GWAS associations of the last 10 years.** The total sample size (left vertical axis) used for the discovery analysis is represented by the blue long-dotted line, whilst the replication sample size represented by the green short-dotted line. The total number of loci is represented by the bars (right vertical axis). The yellow bars represent the number of novel loci reported without independent replication and in pink the total number of novel loci with replication. The numbers in parenthesis after the study (horizontal axis) show the numbers for the novel without replication and the novel loci with replication respectively (yellow/pink).

**Figure 2. Gene ontology enrichment analysis.** The REVIGO graph displays the biological process GO enrichment. Each sphere represents a GO term coloured by the GOfuncR enrichment in the –log10(p-value) scale. The semantic similarity of each GO term is represented by the position of each sphere on the graph. Plot size (sphere size) indicates the frequency of each GO term in which is found in the gene ontology database (i.e. the larger the sphere is the more general the term is). Two clusters are highlighted: A) includes broad intracellular functions such as regulation of intracellular signal transduction, cell cycle, organelle organization, cellular localization, cellular process and transcription; B) the second cluster revealing terms of potential new understanding of the biology underlying blood pressure regulation. Within this cluster, the five major gene ontology terms refer to biosynthesis of nucleobase-containing compounds, organic cyclic compounds, aromatic compounds, cellular nitrogen compounds and heterocyclic compounds.

**Figure 3. Multi-trait associations of blood pressure loci.** BP loci were searched in the GWAS catalog to investigate the pleiotropy of the loci. The heatmap displays a subset of the BP loci with five or more gene associations with at least four traits (excluding blood pressure traits). Ward hierarchical clustering was applied on rows and columns (genes and traits).

**Tables**

|  |  |  |  |
| --- | --- | --- | --- |
| **Table 1 DEPICT tissue enrichment results across all validated blood pressure loci to date and compared to the reported enrichment in Evangelou et al (2018). Results are shown for tissue enrichments with an FDR < 0.05 ordered by nominal -log10 p-value** | | | |
| **Name** | **MeSH second level term** | **Nominal -log10(p-value)** | **Evangelou et all -log10(p-value)** |
| **Myometrium** | **Genitalia** | **14.66** | **9.50** |
| **Arteries** | **Blood Vessels** | **13.72** | **10.84** |
| **Cartilage** | **Cartilage** | **10.53** | **9.03** |
| **Adipose Tissue** | **Connective Tissue** | **10.36** | **8.01** |
| **Genitalia Female** | **Genitalia** | **10.04** | **4.89** |
| **Subcutaneous Fat** | **Connective Tissue** | **9.62** | **7.56** |
| **Adipose Tissue White** | **Connective Tissue** | **9.62** | **7.56** |
| **Genitalia** | **Genitalia** | **9.59** | **4.48** |
| **Uterus** | **Genitalia** | **9.48** | **4.88** |
| **Joint Capsule** | **Skeleton** | **9.19** | **7.12** |
| **Joints** | **Skeleton** | **9.19** | **7.12** |
| **Synovial Membrane** | **Skeleton** | **9.19** | **7.12** |
| **Subcutaneous Fat Abdominal** | **Connective Tissue** | **8.60** | **6.09** |
| **Abdominal Fat** | **Connective Tissue** | **8.60** | **6.09** |
| **Endocrine Glands** | **Endocrine Glands** | **8.38** | **3.67** |
| **Fallopian Tubes** | **Genitalia** | **7.86** | **3.83** |
| **Ovary** | **Genitalia** | **7.76** | **3.30** |
| **Adnexa Uteri** | **Genitalia** | **7.75** | **3.31** |
| **Serous Membrane** | **Membranes** | **7.26** | **4.76** |
| **Gonads** | **Endocrine Glands** | **7.07** | **2.92** |
| **Aortic Valve** | **Heart** | **6.97** | **4.91** |
| **Heart Valves** | **Heart** | **6.97** | **4.91** |
| **Endometrium** | **Genitalia** | **6.97** | **3.44** |
| **Adipocytes** | **Connective Tissue Cells** | **6.03** | **4.24** |
| **Adrenal Glands** | **Endocrine Glands** | **5.76** | **2.99** |
| **Adrenal Cortex** | **Endocrine Glands** | **5.70** | **3.44** |
| **Blood Vessels** | **Blood Vessels** | **5.19** | **4.85** |
| **Stomach** | **Gastrointestinal Tract** | **5.12** | **3.37** |
| **Upper Gastrointestinal Tract** | **Gastrointestinal Tract** | **5.09** | **3.23** |
| **Heart** | **Heart** | **4.89** | **4.57** |
| **Stromal Cells** | **Connective Tissue Cells** | **4.45** | **3.56** |
| **Serum** | **Blood** | **4.40** | **2.92** |
| **Muscle Smooth** | **Muscles** | **4.38** | **3.45** |
| **Heart Atria** | **Heart** | **4.17** | **3.82** |
| **Heart Ventricles** | **Heart** | **4.10** | **4.03** |
| **Veins** | **Blood Vessels** | **4.09** | **3.67** |
| **Lung** | **Lung** | **3.89** | **2.40** |
| **Atrial Appendage** | **Heart** | **3.87** | **3.43** |
| **Pancreas** | **Pancreas** | **3.70** | **3.81** |
| **Mesenchymal Stem Cells** | **Stem Cells** | **3.59** | **2.97** |
| **Chondrocytes** | **Connective Tissue Cells** | **3.54** | **2.00** |
| **Fibroblasts** | **Connective Tissue Cells** | **3.52** | **2.45** |
| **Umbilical Veins** | **Blood Vessels** | **3.50** | **3.13** |
| **Portal System** | **Blood Vessels** | **3.50** | **3.13** |
| **Esophagus** | **Gastrointestinal Tract** | **3.39** | **2.00** |
| **Urinary Bladder** | **Urinary Tract** | **3.26** | **2.84** |
| **Chorion** | **Membranes** | **3.16** | **2.68** |
| **Extraembryonic Membranes** | **Membranes** | **3.16** | **2.68** |
| **Ileum** | **Gastrointestinal Tract** | **3.09** | **3.15** |
| **Endothelial Cells** | **Epithelial Cells** | **3.09** | **2.80** |
| **Urinary Tract** | **Urinary Tract** | **3.02** | **3.21** |
| **Osteoblasts** | **Connective Tissue Cells** | **3.01** | **3.46** |
| **Exocrine Glands** | **Exocrine Glands** | **2.92** |  |
| **Kidney Cortex** | **Urinary Tract** | **2.89** | **2.07** |
| **Prostate** | **Exocrine Glands** | **2.80** |  |
| **Kidney** | **Urinary Tract** | **2.76** | **2.97** |
| **Intestine Small** | **Gastrointestinal Tract** | **2.75** | **2.81** |
| **Genitalia Male** | **Genitalia** | **2.61** |  |
| **Cecum** | **Gastrointestinal Tract** | **2.46** |  |
| **Islets of Langerhans** | **Pancreas** | **2.13†** |  |
| **Cervical Vertebrae** | **Skeleton** | **2.06†** |  |
| **Spine** | **Skeleton** | **2.01†** |  |
| **Cervix Uteri** | **Genitalia** | **1.70†** |  |
| **Skin** | **Skin** | **1.70†** |  |
| **Lower Gastrointestinal Tract** | **Gastrointestinal Tract** | **1.70†** |  |
| **FDR: False discovery rate; Significant tissue enrichment threshold set at an FDR < 5%. † MeSH terms with an FDR ≥ 1% and below 5%, all others represent an FDR < 1% MeSH term: Medical Subject Heading term.** | | | |

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Table 2. GSEA: Gene set enrichment analysis. Results shown for the top 20 enriched gene sets. All sets observed with an at an FDR threshold below or equal to 0.05.** | | | | | |
| **Gene Set Name** | **# Genes in Gene Set (K)** | **Description** | **# Genes in Overlap (k)** | **k/K** | **p-value** |
| **REACTOME\_SIGNALING\_BY\_GPCR** | **920** | **Genes involved in Signalling by GPCR** | **107** | **0.1163** | **4.87E-27** |
| **REACTOME\_GPCR\_DOWNSTREAM\_SIGNALING** | **805** | **Genes involved in GPCR downstream signalling** | **98** | **0.1217** | **2.32E-26** |
| **KEGG\_PATHWAYS\_IN\_CANCER** | **328** | **Pathways in cancer** | **51** | **0.1555** | **8.23E-19** |
| **REACTOME\_DEVELOPMENTAL\_BIOLOGY** | **396** | **Genes involved in Developmental Biology** | **54** | **0.1364** | **3.07E-17** |
| **NABA\_MATRISOME** | **1028** | **Ensemble of genes encoding extracellular matrix and extracellular matrix-associated proteins** | **95** | **0.0924** | **3.06E-17** |
| **REACTOME\_OLFACTORY\_SIGNALING\_PATHWAY** | **328** | **Genes involved in Olfactory Signalling Pathway** | **45** | **0.1372** | **1.06E-14** |
| **KEGG\_PROSTATE\_CANCER** | **89** | **Prostate cancer** | **23** | **0.2584** | **4.72E-14** |
| **REACTOME\_HEMOSTASIS** | **466** | **Genes involved in Hemostasis** | **54** | **0.1159** | **3.28E-14** |
| **KEGG\_OLFACTORY\_TRANSDUCTION** | **389** | **Olfactory transduction** | **48** | **0.1234** | **8.33E-14** |
| **KEGG\_DILATED\_CARDIOMYOPATHY** | **92** | **Dilated cardiomyopathy** | **23** | **0.25** | **1.02E-13** |
| **KEGG\_HYPERTROPHIC\_CARDIOMYOPATHY\_HCM** | **85** | **Hypertrophic cardiomyopathy (HCM)** | **22** | **0.2588** | **1.62E-13** |
| **KEGG\_ARRHYTHMOGENIC\_RIGHT\_VENTRICULAR\_CARDIOMYOPATHY\_ARVC** | **76** | **Arrhythmogenic right ventricular cardiomyopathy (ARVC)** | **20** | **0.2632** | **1.45E-12** |
| **NABA\_CORE\_MATRISOME** | **275** | **Ensemble of genes encoding core extracellular matrix including ECM glycoproteins, collagens and proteoglycans** | **38** | **0.1382** | **9.75E-13** |
| **KEGG\_WNT\_SIGNALING\_PATHWAY** | **151** | **Wnt signalling pathway** | **27** | **0.1788** | **4.32E-12** |
| **KEGG\_CHRONIC\_MYELOID\_LEUKEMIA** | **73** | **Chronic myeloid leukemia** | **19** | **0.2603** | **6.48E-12** |
| **KEGG\_FOCAL\_ADHESION** | **201** | **Focal adhesion** | **31** | **0.1542** | **6.60E-12** |
| **KEGG\_MAPK\_SIGNALING\_PATHWAY** | **267** | **MAPK signalling pathway** | **35** | **0.1311** | **3.43E-11** |
| **KEGG\_CALCIUM\_SIGNALING\_PATHWAY** | **178** | **Calcium signalling pathway** | **28** | **0.1573** | **4.21E-11** |
| **KEGG\_SMALL\_CELL\_LUNG\_CANCER** | **84** | **Small cell lung cancer** | **19** | **0.2262** | **9.28E-11** |
| **KEGG\_ADHERENS\_JUNCTION** | **75** | **Adherens junction** | **18** | **0.24** | **1.01E-10** |

**Abbreviations**

Blood pressure (BP)

Cardiovascular disease (CVD)

Diastolic blood pressure (DBP)

Gene ontology (GO)

Gene-set Enrichment Analysis (GSEA)

Genetic Epidemiology Research on Adult Health and Aging cohort (GERA)

Genome-wide association studies (GWAS)

International Consortium of Blood Pressure (ICBP)

Linkage disequilibrium (LD)

MAF minor allele frequency

Million Veteran Program (MVP)

Single nucleotide polymorphism (SNP)

Systolic blood pressure (SBP)

UK Biobank (UKB)